Acorda Therapeutics (ACOR) Revenue & Revenue Breakdown
Acorda Therapeutics Revenue Highlights
Latest Revenue (Y)
$102.42M
Latest Revenue (Q)
$20.29M
Main Segment (Y)
Product
Acorda Therapeutics Revenue by Period
Acorda Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $102.42M | -13.62% |
| 2022-12-31 | $118.57M | -8.14% |
| 2021-12-31 | $129.07M | -15.62% |
| 2020-12-31 | $152.97M | -20.50% |
| 2019-12-31 | $192.41M | -59.19% |
| 2018-12-31 | $471.43M | -19.86% |
| 2017-12-31 | $588.29M | 13.22% |
| 2016-12-31 | $519.60M | 5.47% |
| 2015-12-31 | $492.66M | 22.71% |
| 2014-12-31 | $401.48M | 19.34% |
| 2013-12-31 | $336.43M | 10.01% |
| 2012-12-31 | $305.81M | 4.65% |
| 2011-12-31 | $292.24M | 53.00% |
| 2010-12-30 | $191.00M | 249.36% |
| 2009-12-31 | $54.67M | 14.31% |
| 2008-12-31 | $47.83M | 21.12% |
| 2007-12-31 | $39.49M | 44.37% |
| 2006-12-31 | $27.35M | 431.55% |
| 2005-12-31 | $5.15M | 973.11% |
| 2004-12-31 | $479.50K | -43.98% |
| 2003-12-31 | $856.00K | - |
Acorda Therapeutics generated $102.42M in revenue during NA 2023, up -13.62% compared to the previous quarter, and up 21.73% compared to the same period a year ago.
Acorda Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $20.29M | -46.59% |
| 2023-12-31 | $37.98M | 37.06% |
| 2023-09-30 | $27.71M | -6.60% |
| 2023-06-30 | $29.68M | 33.32% |
| 2023-03-31 | $22.26M | -29.28% |
| 2022-12-31 | $31.47M | -6.08% |
| 2022-09-30 | $33.51M | 7.92% |
| 2022-06-30 | $31.05M | 37.80% |
| 2022-03-31 | $22.53M | -39.04% |
| 2021-12-31 | $36.97M | 17.52% |
| 2021-09-30 | $31.46M | -1.04% |
| 2021-06-30 | $31.79M | 10.13% |
| 2021-03-31 | $28.86M | -24.37% |
| 2020-12-31 | $38.16M | -28.12% |
| 2020-09-30 | $53.09M | 57.93% |
| 2020-06-30 | $33.62M | 19.64% |
| 2020-03-31 | $28.10M | -44.35% |
| 2019-12-31 | $50.50M | 5.81% |
| 2019-09-30 | $47.72M | -4.66% |
| 2019-06-30 | $50.05M | 13.40% |
| 2019-03-31 | $44.14M | -36.17% |
| 2018-12-31 | $69.15M | -51.58% |
| 2018-09-30 | $142.81M | -6.84% |
| 2018-06-30 | $153.30M | 44.40% |
| 2018-03-31 | $106.17M | -43.65% |
| 2017-12-31 | $188.40M | 33.55% |
| 2017-09-30 | $141.06M | 1.17% |
| 2017-06-30 | $139.44M | 16.80% |
| 2017-03-31 | $119.39M | -15.10% |
| 2016-12-31 | $140.63M | 3.70% |
| 2016-09-30 | $135.61M | 6.40% |
| 2016-06-30 | $127.46M | 9.97% |
| 2016-03-31 | $115.90M | -11.46% |
| 2015-12-31 | $130.90M | -11.67% |
| 2015-09-30 | $148.20M | 30.33% |
| 2015-06-30 | $113.71M | 13.88% |
| 2015-03-31 | $99.85M | -15.29% |
| 2014-12-31 | $117.87M | 11.24% |
| 2014-09-30 | $105.96M | 9.09% |
| 2014-06-30 | $97.13M | 20.63% |
| 2014-03-31 | $80.52M | -13.04% |
| 2013-12-31 | $92.59M | 9.04% |
| 2013-09-30 | $84.92M | -2.45% |
| 2013-06-30 | $87.05M | 21.13% |
| 2013-03-31 | $71.86M | -11.79% |
| 2012-12-31 | $81.47M | 5.21% |
| 2012-09-30 | $77.44M | 2.35% |
| 2012-06-30 | $75.66M | 6.19% |
| 2012-03-31 | $71.25M | -1.92% |
| 2011-12-31 | $72.64M | -21.91% |
| 2011-09-30 | $93.03M | 42.52% |
| 2011-06-30 | $65.28M | 6.51% |
| 2011-03-31 | $61.29M | -8.25% |
| 2010-12-30 | $66.80M | 5.00% |
| 2010-09-30 | $63.62M | 48.53% |
| 2010-06-30 | $42.84M | 141.36% |
| 2010-03-31 | $17.75M | 22.90% |
| 2009-12-31 | $14.44M | -5.08% |
| 2009-09-30 | $15.21M | 21.23% |
| 2009-06-30 | $12.55M | 0.64% |
| 2009-03-31 | $12.47M | 0.06% |
| 2008-12-31 | $12.46M | -0.03% |
| 2008-09-30 | $12.47M | 9.48% |
| 2008-06-30 | $11.39M | -1.11% |
| 2008-03-31 | $11.51M | 2.66% |
| 2007-12-31 | $11.22M | - |
Acorda Therapeutics generated $20.29M in revenue during Q1 2024, up -46.59% compared to the previous quarter, and up 64.47% compared to the same period a year ago.
Acorda Therapeutics Revenue Breakdown
Acorda Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $102.42M | $103.84M | $114.19M | $124.83M | $180.74M |
| Royalty | $15.11M | $14.88M | $13.14M | $11.67M | - |
| Ampyra | $63.94M | $84.56M | $98.89M | $163.16M | - |
| License Revenue | $99.00K | - | - | - | - |
| License | - | $500.00K | - | - | - |
| Inbrija | - | - | $29.63M | $24.23M | $15.30M |
| Milestone Revenue1 | - | - | - | $15.00M | - |
| Other Product | - | - | - | $1.71M | $2.27M |
Acorda Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (56.41%), Ampyra (35.21%), Royalty (8.32%), and License Revenue (0.05%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inbrija | $4.72M | $8.09M | $8.29M | $5.59M | $3.67M | $10.39M | $7.80M | $6.44M | $5.00M | $9.33M | $5.83M | $4.71M | $4.35M | $6.14M | $4.89M | $3.01M | - | - | - | - |
| Royalty | $2.39M | $5.40M | $2.50M | $3.69M | $3.53M | $3.65M | $3.05M | $3.57M | $3.96M | $4.08M | $3.60M | $3.59M | $3.62M | $3.48M | $3.40M | $2.82M | $3.43M | $3.09M | $2.92M | $2.86M |
| Product | $17.88M | $32.56M | $25.18M | $25.96M | $18.72M | $27.82M | $29.96M | $27.48M | $18.57M | $32.89M | $27.85M | $28.20M | $25.25M | $34.68M | $34.69M | $30.79M | $24.67M | $47.41M | $44.80M | $47.19M |
| License Revenue | $23.00K | $31.00K | $34.00K | $23.00K | $11.00K | $500.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Ampyra | $11.50M | $18.70M | $15.72M | $16.91M | $12.61M | $21.11M | $18.18M | $14.90M | $22.52M | $20.03M | $21.76M | $20.25M | $25.34M | $27.34M | $26.08M | $20.12M | $40.78M | $37.65M | $44.18M | - |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Product | - | - | - | - | - | - | - | - | - | - | $21.00K | - | $1.00K | $5.00K | $1.51M | - | $194.00K | $493.00K | $2.26M | - |
| Milestone | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.00M | - | - | - | - | - |
Acorda Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.98%), Ampyra (31.49%), Inbrija (12.93%), Royalty (6.54%), and License Revenue (0.06%).
Acorda Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| ACOR | Acorda Therapeutics | $102.42M | $20.29M |
| DERM | Journey Medical | $79.18M | $14.86M |
| CPIX | Cumberland Pharmaceuticals | $39.55M | $9.85M |
| BFRI | Biofrontera | $34.01M | $7.83M |
| UPC | Universe Pharmaceuticals | $32.31M | $13.84M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| SNOA | Sonoma Pharmaceuticals | $12.73M | $3.44M |
| JUPW | Safety Shot | $6.20M | $910.01K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| AKAN | Akanda | $2.16M | $762.61K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
| PRFX | PainReform | - | - |
ACOR Revenue FAQ
What is Acorda Therapeutics’s yearly revenue?
Acorda Therapeutics's yearly revenue for 2023 was $102.42M, representing a decrease of -13.62% compared to 2022. The company's yearly revenue for 2022 was $118.57M, representing a decrease of -8.14% compared to 2021. ACOR's yearly revenue for 2021 was $129.07M, representing a decrease of -15.62% compared to 2020.
What is Acorda Therapeutics’s quarterly revenue?
Acorda Therapeutics's quarterly revenue for Q1 2024 was $20.29M, a -46.59% decrease from the previous quarter (Q4 2023), and a -8.85% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $37.98M, a 37.06% increase from the previous quarter (Q3 2023), and a 20.69% increase year-over-year (Q4 2022). ACOR's quarterly revenue for Q3 2023 was $27.72M, a -6.60% decrease from the previous quarter (Q2 2023), and a -17.30% decrease year-over-year (Q3 2022).
What is Acorda Therapeutics’s revenue growth rate?
Acorda Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -20.65%, and for the last 5 years (2019-2023) was -46.77%.
What are Acorda Therapeutics’s revenue streams?
Acorda Therapeutics's revenue streams in c 23 are Product, Royalty, Ampyra, and License Revenue. Product generated $102.42M in revenue, accounting 56.41% of the company's total revenue, down -1.37% year-over-year. Royalty generated $15.11M in revenue, accounting 8.32% of the company's total revenue, up 1.55% year-over-year. Ampyra generated $63.94M in revenue, accounting 35.21% of the company's total revenue, down -24.38% year-over-year. License Revenue generated $99K in revenue, accounting 0.05% of the company's total revenue
What is Acorda Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Acorda Therapeutics was Product. This segment made a revenue of $102.42M, representing 56.41% of the company's total revenue.